Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) still represents one of the most challenging early complications after hematopoietic stem cell transplantation (HSCT), associated with high morbidity and mortality [1, 2]. Defibrotide (DF) is approved for SOS/VOD treatment, whereas its prophylactic use is beyond the approved indications of the drug.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Marta
Contact Marta, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack